Success Metrics

Clinical Success Rate
78.9%

Based on 15 completed trials

Completion Rate
79%(15/19)
Active Trials
7(19%)
Results Posted
20%(3 trials)
Terminated
4(11%)

Phase Distribution

Ph phase_1
2
5%
Ph not_applicable
2
5%
Ph phase_4
19
51%
Ph phase_2
4
11%
Ph phase_3
8
22%

Phase Distribution

2

Early Stage

4

Mid Stage

27

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
2(5.7%)
Phase 2Efficacy & side effects
4(11.4%)
Phase 3Large-scale testing
8(22.9%)
Phase 4Post-market surveillance
19(54.3%)
N/ANon-phased studies
2(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.9%

15 of 19 finished

Non-Completion Rate

21.1%

4 ended early

Currently Active

7

trials recruiting

Total Trials

37

all time

Status Distribution
Active(11)
Completed(15)
Terminated(4)
Other(7)

Detailed Status

Completed15
unknown7
Recruiting6
Not yet recruiting4
Terminated4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
7
Success Rate
78.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (5.7%)
Phase 24 (11.4%)
Phase 38 (22.9%)
Phase 419 (54.3%)
N/A2 (5.7%)

Trials by Status

unknown719%
completed1541%
active_not_recruiting13%
not_yet_recruiting411%
terminated411%
recruiting616%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT06769256Phase 4

Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden

Recruiting
NCT07537933Phase 3

Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion

Not Yet Recruiting
NCT06037889Phase 3

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Completed
NCT07493577Phase 1

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

Not Yet Recruiting
NCT06265051Phase 2

Tirofiban After Successful MT Recanalization in AIS

Completed
NCT05225961Phase 4

ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion

Active Not Recruiting
NCT07379190Phase 3

HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)

Not Yet Recruiting
NCT06045156Not Applicable

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Recruiting
NCT05728333Phase 2

Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke

Recruiting
NCT07290751Phase 4

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

Recruiting
NCT06238115Phase 2

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Completed
NCT07026318Not Applicable

Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke

Recruiting
NCT07111806Phase 3

Intravenous Tirofiban After Delayed Thrombolysis in Stroke

Not Yet Recruiting
NCT06319846Phase 3

Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4)

Recruiting
NCT03048019

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Terminated
NCT05841147Phase 4

Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban

Unknown
NCT03357133Phase 2

Tirofiban for Patients Treated With Alteplase

Terminated
NCT02978040Phase 4

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Completed
NCT03797729Phase 4

Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.

Unknown
NCT02131220Phase 4

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Completed

Drug Details

Intervention Type
DRUG
Total Trials
37